Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

MDPI full text link MDPI Free PMC article
Full text links

Actions

Share

Review
.2023 Jul 13;11(7):1977.
doi: 10.3390/biomedicines11071977.

Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders

Affiliations
Review

Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders

Savelii R Kuvarzin et al. Biomedicines..

Abstract

All antipsychotics currently used in clinic block D2 dopamine receptors. Trace amine-associated receptor 1 is emerging as a new therapeutic target for schizophrenia and several other neuropsychiatric disorders. SEP-363856 (International Nonproprietary Name: Ulotaront) is an investigational antipsychotic drug with a novel mechanism of action that does not involve antagonism of dopamine D2 receptors. Ulotaront is an agonist of trace amine-associated receptor 1 and serotonin 5-HT1A receptors, but can modulate dopamine neurotransmission indirectly. In 2019, the United States Food and Drug Administration granted Breakthrough Therapy Designation for ulotaront for the treatment of schizophrenia. Phase 2 clinical studies indicated that ulotaront can reduce both positive and negative symptoms of schizophrenia without causing the extrapyramidal or metabolic side effects that are inherent to most currently used antipsychotics. At present, it is in phase 3 clinical development for the treatment of schizophrenia and is expected to be introduced into clinical practice in 2023-2024. Clinical studies evaluating the potential efficacy of ulotaront in Parkinson's disease psychosis, generalized anxiety disorder, and major depressive disorder have also been started. The aim of this scoping review is to summarize all currently available preclinical and clinical evidence on the utility of ulotaront in the treatment of schizophrenia. Here, we show the main characteristics and distinctive features of this drug. Perspectives and limitations on the potential use of ulotaront in the pharmacotherapy of several other neuropsychiatric disorders are also discussed.

Keywords: SEP-363856; TAAR; antipsychotic agents; dopamine; neuropsychiatric disorders; schizophrenia; trace amine-associated receptor 1; ulotaront.

PubMed Disclaimer

Conflict of interest statement

Raul R. Gainetdinov is a consultant for Sunovion Pharmaceuticals Inc. Savelii R. Kuvarzin, Ilya Sukhanov, Kirill Onokhin, and Konstantin Zakharov declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Kahn R.S., Sommer I.E., Murray R.M., Meyer-Lindenberg A., Weinberger D.R., Cannon T.D., O’Donovan M., Correll C.U., Kane J.M., van Os J., et al. Schizophrenia. Nat. Rev. Dis. Primers. 2015;1:15067. doi: 10.1038/nrdp.2015.67. - DOI - PubMed
    1. Correll C.U., Abi-Dargham A., Howes O. Emerging Treatments in Schizophrenia. J. Clin. Psychiatry. 2022;83:SU21204IP1. doi: 10.4088/JCP.SU21204IP1. - DOI - PubMed
    1. Tajti J., Szok D., Csáti A., Szabó Á., Tanaka M., Vécsei L. Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain. Int. J. Mol. Sci. 2023;24:4114. doi: 10.3390/ijms24044114. - DOI - PMC - PubMed
    1. Battaglia S., Nazzi C., Thayer J.F. Fear-Induced Bradycardia in Mental Disorders: Foundations, Current Advances, Future Perspectives. Neurosci. Biobehav. Rev. 2023;149:105163. doi: 10.1016/j.neubiorev.2023.105163. - DOI - PubMed
    1. Brasso C., Colli G., Sgro R., Bellino S., Bozzatello P., Montemagni C., Villari V., Rocca P. Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review. Biomedicines. 2023;11:921. doi: 10.3390/biomedicines11030921. - DOI - PMC - PubMed

Publication types

Related information

Grants and funding

LinkOut - more resources

Full text links
MDPI full text link MDPI Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp